Neuropathic Ocular Pain Nop Epidemiology Forecast Insight

DelveInsight’s ‘Neuropathic Ocular Pain (NOP)—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the NOP, historical and forecasted epidemiology as well as the NOP trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Neuropathic Ocular Pain (NOP) Disease Understanding

Neuropathic ocular pain (NOP), also referred to as corneal neuropathic pain, is a condition in which corneal pain is seen in response to normally non-painful stimuli. This pain results from repeated direct damage to corneal nerves. Aberrant regeneration with upregulation of nociceptors responsible for the processing of painful stimuli leads to hyper-responsivity and increased perception of pain in response to even normally unpainful stimuli. The distorted neuronal excitability which persists even after the tissue has healed is the basis of symptoms of self-sustained chronic corneal pain persisting even in the absence of stimuli and clinical signs – the so-called corneal “pain without stain” or “phantom cornea.” This condition is the ocular analog of systemic neuropathic pain, complex regional pain syndrome, or reflex sympathetic dystrophy (RSD).

 

Symptoms of NOP include a host of ocular pain symptoms that have been described as dryness (with minimal or no relief with over-the-counter lubricating drops), burning, shooting, pressure-like pain, foreign body sensation, grittiness, aching, stabbing or cutting sensation and/or throbbing. Pain may occur spontaneously or be evoked by light (e.g., fluorescent room lights, sunlight), wind (e.g., indoor fans, in-clinic “air puff test” for eye pressure), and/or temperature changes (e.g., air conditioning, hairdryers, seasonal variation). One or both eyes may be involved. The onset may be sudden, as is usually when there is an identifiable trigger (such as trauma or surgery to the eye) or insidious. While the pain is typically chronic, its severity can range from mild to excruciating.

Continued in the report…..

Neuropathic Ocular Pain (NOP) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Several Eye Disorders and surgeries, and Total Cases of Neuropathic Ocular Pain (NOP) scenario in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan from 2018 to 2030.

Neuropathic Ocular Pain (NOP) Detailed Epidemiology Segmentation

  • In 2020, the total cases of Neuropathic Ocular Pain (NOP) were 2,904,412 cases in the 7MM, which might increase by 2030.
  • In 2020 the US accounted for 664,826 NOP cases, which is anticipated to increase by 2030.
  • In 2020, the EU5 countries accounted for 1,549,516 cases, which is seen to increase by 2030.
  • Among EU5 countries, Italy had the highest number of cases of Neuropathic Ocular Pain (NOP), which were 522,268 cases in 2020. As per DelveInsight’s estimates, this count will increase through the study period.
  • Japan, in 2020, accounted for 690,070 cases of NOP, which will decrease by the year 2030.

Scope of the Report

  • The report covers the descriptive overview of NOP, explaining its causes, symptoms, pathophysiology, and other aspects.
  • The report provides insight into the 7MM, historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Neuropathic Ocular Pain (NOP).
  • The report helps to recognize the growth opportunities in the 7MM, with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM, by Total Cases of Several Eye Disorders, and Total Cases of Neuropathic Ocular Pain (NOP).

Report Highlights

  • 10-Year Forecast of NOP
  • 7MM Coverage
  • Total Cases of Several Eye Disorders
  • Total Cases of Neuropathic Ocular Pain (NOP)

Key Questions Answered

  • What are the disease risk, and burden of NOP?
  • What is the historical NOP patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), Japan?
  • What would be the forecasted patient pool of NOP at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to NOP?
  • Out of the above-mentioned countries, which country would have the highest cases of NOP during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM, during the forecast period (2021–2030)?

Reasons to buy

The Neuropathic Ocular Pain (NOP) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM, NOP epidemiology forecast.
  • The NOP epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The NOP epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Future Prospects

4. Executive Summary of Neuropathic Ocular Pain (NOP)

5. Key Events

6. Neuropathic ocular pain (NOP): Disease Background and Overview

6.1. Introduction

6.2. Symptoms

6.3. Types

6.4. Causes

6.5. Pathophysiology of Neuropathic Corneal Pain

6.6. Diagnosis and Differential Diagnosis

6.6.1. Ocular Pain Questionnaires to Assess Symptoms

6.6.2. Functional Somatosensory Testing

6.6.3. Clinical Examination

6.6.4. In Vivo Confocal Microscopy (IVCM) to Confirm Corneal Nerve Damage

6.7. Treatment and Management

6.7.1. Neuroregenerative Therapy

6.7.1.1. Autologous Serum Tears (AST)

6.7.2. Anti-Inflammatory Therapy

6.7.3. Ocular Surface Rehabilitation and Managing Comorbidities

6.7.3.1. Self-Retained Cryopreserved Amniotic Membrane (CAM)

6.7.3.2. Protective Contact Lenses

6.7.4. Systemic Pharmacotherapy

6.7.4.1. First-Line Agents

6.7.4.2. Second Line Agents

6.7.4.3. Third Line Agents

6.7.5. Alternative Therapy

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Methodology

7.3. Assumptions and Rationale: 7MM

7.4. Total Cases of Several Eye Disorders and Surgeries in the 7MM

7.5. Total Cases of Neuropathic Ocular Pain (NOP) in Several Eye Disorders and Surgeries in the 7MM

7.6. The United States

7.6.1. Number of Cases of Several Eye Disorders and Surgeries in the United States

7.6.2. Number of Cases of NOP in Several Eye Disorders and Surgeries in the United States.

7.7. EU5

7.7.1. Number of Cases of Several Eye Disorders and Surgeries in EU-5

7.7.2. Number of Cases of NOP in Several Eye Disorders and Surgeries in EU-5

7.8. Japan

7.8.1. Number of Cases of Several Eye Disorders and Surgeries in Japan

7.8.2. Number of Cases of NOP in Several Eye Disorders and Surgeries in Japan

8. Appendix

8.1. Report Methodology

8.2. Bibliography

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Table

Table 1: Summary of NOP Market and Epidemiology (2018–2030)

Table 2: Key Events

Table 3: Incidence of Neuropathic Ocular pain in individuals with predisposing conditions

Table 4: Total Cases of Several Eye Disorders and Surgeries in the 7MM (2018–2030)

Table 5: Total Cases of Neuropathic Ocular Pain (NOP) in Several Eye Disorders and Surgeries in the 7MM (2018–2030)

Table 6: Number of Cases of Several Eye Disorders and Surgeries in the United States (2018–2030)

Table 7: Number of Cases of NOP in Several Eye Disorders and Surgeries in the United States (2018–2030)

Table 8: Number of Cases of Several Eye Disorders and Surgeries in EU-5 (2018–2030)

Table 9: Number of Cases of NOP in Several Eye Disorders and Surgeries in EU-5 (2018–2030)

Table 10: Number of Cases of Several Eye Disorders and Surgeries in Japan (2018–2030)

Table 11: Number of Cases of NOP in Several Eye Disorders and Surgeries in Japan (2018–2030)

List of Figures

Figure 1: Symptoms of Neuropathic Ocular Pain

Figure 2: Types of Neuropathic Ocular Pain

Figure 3: Causes of Neuropathic Ocular Pain

Figure 4: Clinical Assessment Approach for Patients With Neuropathic Corneal Pain

Figure 5: Diagnosis of Neuropathic Corneal Pain

Figure 6: Corneal Laser in vivo Confocal Microscopy Images of Patients with Neuropathic Corneal Pain

Figure 7: Treatment and management of Neuropathic Ocular Pain

Figure 8: Total Cases of Several Eye Disorders and Surgeries in the 7MM (2018–2030)

Figure 9: Total Cases of Neuropathic Ocular Pain (NOP) in Several Eye Disorders and Surgeries in the 7MM (2018–2030)

Figure 10: Number of Cases of Several Eye Disorders and Surgeries in the United States (2018–2030)

Figure 11: Number of Cases of NOP in Several Eye Disorders and Surgeries in the United States (2018–2030)

Figure 12: Number of Cases of Several Eye Disorders and Surgeries in EU-5 (2018–2030)

Figure 13: Number of Cases of NOP in Several Eye Disorders and Surgeries in EU-5 (2018–2030)

Figure 14: Number of Cases of Several Eye Disorders and Surgeries in Japan (2018–2030)

Figure 15: Number of Cases of NOP in Several Eye Disorders and Surgeries in Japan (2018–2030)

Forward to Friend

Need A Quote